The percentage of MOG181–189:HLA-A2 CD8+ T cells expressing CD20 was significantly increased in MS patients (21.2 ± 7.8%) compared to HLA allele-matched controls (0.0 ± 0.0%) (Fig. 3B). This evidence concerns the gene CD8A and myeloid sarcoma.